European Psychiatry - Volume 41 - April 2017

140 / 916

S136 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169
Disclosure of interest This work did not receive funding from
external sources. Over the past few years, Dr. Fineberg has received
financial support in various forms fromthe following: Shire, Otsuka,
Lundbeck, Glaxo-SmithKline, Servier, Cephalon, Astra Zeneca, Jazz
pharmaceuticals, Bristol Myers Squibb, Novartis, Medical Research
Council (UK), National Institute for HealthResearch (UK),Wellcome
Foundation, European College of Neuropsychopharmacology, UK
College of Mental Health Pharmacists, British Association for Psy-
chopharmacology, International College of Obsessive-Compulsive
Spectrum Disorders, International Society for Behavioural Addic-
tion, World Health Organization, Royal College of Psychiatrists.
EW0091
Psychiatric co-morbidities in a French
cohort of adults with
high-functioning autism (HFA)
A. Gaman ∗, O. Godin , I. Scheid , D. Monnet ,
E. Murzi , A. Martinez Teruel , F. Amsellem ,
H. Laouamri , K. Souyris , J. Houneou , T. Infor ,
R. Delorme , M. Leboyer
1 Hopital Albert Chenevier AP–HP, Psychiatry, Créteil, France
2 Inserm, U955 Translational Psychiatry, Paris, France
3 Fondation Fondamental, Centre Expert Asperger, Paris, France
4 Fondation Fondamental, Informatics and Data Base, Paris, France
5 Institute Pasteur, Human Genetics and Cognitive Studies, Paris,
France
6 Hôpital “Robert Debré”, Child and Adolescent Psychiatry, Paris,
France
7 Neurospin, Uniact Psychiatry Team, Paris, France
8 Roche, Cooperative Group, Basel, France
∗ Corresponding author.
Background and rationale Psychiatric co-morbidities are shown
to be very prevalent in patients diagnosed with Autism Spec-
trum Disorder (ASD), up high to 53% for mood, 50% anxiety
and 43% for ADHD disorders in an European cohort of adults
with HFA. Using a new approach, our study proposes to explore
aspects of co-morbidities in the largest French cohort of HFA adults
(C0733/InfoR) by implying qualitative and quantitative clinical
tools.
Aims To explore: (1) the prevalence rates of psychiatric co-
morbidities; (2) the interplay between co-morbidities and the ASD
symptoms.
Methods Diagnosis was made according to DSM 5 criteria.
Dimensional evaluation used Social Responsiveness Scale (SRS),
Systemizing Quotient (SQ) and Empathy Quotient (EQ). We used
T-test, Mann–Whitney test and linear regression models.
Results We included 103 patients (mean age 29.3, sex ratio M/F:
3.4:1). Lifetime prevalence rates of 53.5% for depressive disorder
73.5% for anxiety disorders and 37.5% for ADHD were found. Sub-
jects with psychotic co-morbid symptoms had a more severe social
deficit (SRS score 66.2 vs 77.9 P < 0.05); patients with ADHD, lower
cognition (mean IQ total 107.7 vs 99.0 P < 0.05). SQs (P < 0.05) were
significantly higher in patients with co-morbid psychosis, dys-
thymia, suicide attempts, and depressive disorders and directly
correlated with age (ˇ = 0.35, P< 0.05). SQ and EQ were inversely
correlated.
Discussion The results reproduce the high prevalence of co-
morbidities in other studies and explore its association with social
functioning and cognition. Identification of associated psychiatric
conditions in subjects with HFA is therefore a crucial clinical issue
potentially guiding the treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0092
Group experience and dual pathology
and addictions in a regional hospital
in Spain
M.G. García Jiménez
Psychiatrist, Madrid, Spain
Introduction Dual pathology is a term applied to those subjects
suffering simultaneously fromaddiction and othermental disorder.
Group psychotherapy can be used in people who have both diag-
noses with good results in improvement of addiction and disease
stabilization.
Objectives The purpose of this study is to analyse to efficacy of
a group of psychotherapy for patients with alcohol addiction and
other mental disorder, and analyse the presence of personality dis-
order in this group and how it affects its evolution.
Methods The study was conducted on a sample of 16 patients
diagnosed with alcohol abuse or dependence with psychiatric
co-morbidity who attended a therapy group for 6 months from
January16 to June16. The study was conducted in ambulatory care
(outpatient), being an open and heterogeneous group.
Results Main diagnosis was unspecified personality disorder and
mood disorder (25%) followed by borderline personality disorder
and mood disorder (18.75%), attention deficit disorder and hyper-
activity (18.75%), mood disorder (12.5%), substance use disorder
without other psychiatric co-morbidity (12.5%), narcissistic per-
sonality disorder (6.25%) and impulse control disorder (6.25%).
Regarding progress in the stages of change, results were as fol-
lows: 31.5% of patients progressed to the stage of preparation for
action, 25% alternating periods of abstinence from alcohol with
brief relapse, 25% advanced to the stage of action, 18.5% managed
to stay alcohol withdrawn.
Conclusions In our sample, we can conclude that a therapeutic
group including patients at different stages of change and diag-
noses is positive. At the end, improvement in mood and anxiety
was observed.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW0093
The impact of cannabis in
Schizophrenia: Pafip three-year
longitudinal study on outcome and
functionality after a first episode of
psychosis
M. Gomez Revuelta ∗, M. Juncal Ruiz , O. Porta Olivares ,
M. Fernández Rodríguez , D. Abejas Díez , L. Sánchez Blanco ,
R. Landera Rodríguez , R. Medina Blanco , B. Crespo Facorro ,
I. Madrazo Del Río Hortega , R. Gutierrez Martin
1 Hospital Universitario de Álava-Sede Santiago, Vitoria-Gasteiz,
Psychiatry, Vitoria-Gasteiz, Spain
2 Hospital Universitario Marqués de Valdecilla, Psychiatry,
Santander, Spain
∗ Corresponding author.
Introduction The association between cannabis and psychosis
makes crucial the intervention on cannabis use disorder at first
episodes of psychosis (FEP), especially among young population. In
this group of patients, the harmful potential of cannabis ismore evi-
dent by its influence on neurodevelopment. However, the nature of
the association cannabis-psychosis is not clearly described. It seems
to represent a mediating factor for an increased risk of psychosis
in healthy and high-risk populations, determining an earlier age of
onset and worsening long term outcome.
Objectives To assess the impact of cannabis in terms of functional
and clinical prognosis in patients recruited after a FEP.